LAGOS, Nigeria, Aug. 22, 2025 /PRNewswire/ -- BSV has launched a "Voice of Africa" awareness campaign in African countries to publicise HDFN. Continue Reading BSV launches the "Voice of Africa" series to raise public awareness of HDFN (PRNewsfoto/BSV) What is HDFN and why is it essential to understand it? Haemolytic disease neonatal (HDFN), also known as erythroblastosis foetalis, is a blood disorder that occurs when the blood groups of the mother and child are incompatible. This incompatibilit

PITTSBURGH, PA, USA I August 21, 2025 I Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance following inhaled or intratumoral delivery to solid tumors. Based on promising early

Talks between drugmakers and the UK government over a controversial medicines payment scheme have broken down without an agreement being reached. The Association of the British Pharmaceutical Industry (ABPI) confirmed the news on Friday, despite what it said were "best efforts" from both sides.In April, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG). Under the scheme — which has bee

AbbVie is planning regulatory submissions for Rinvoq (upadacitinib) to treat hair loss after it shared that the JAK inhibitor has now succeeded in both Phase III trials comprising the UP-AA clinical programme.The results of Study 1 were reported Thursday, less than a month after AbbVie announced that the programme's Study 2 met its clinical endpoint. The two replicate pivotal studies enrolled 1,399 patients between the ages of 12 and 64 with severe alopecia areata (AA) and a mean baseline scalp

iStock, Olena Koliesnik Krystal Biotech’s decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal Biotech’s KB707. The biotech said this has introduced “heightened uncertainty” regarding a potential accelerated pathway for the candidate. Krystal Biotech has discontinued a Phase I/II study of its investigational intratumoral therapy KB707, which the Pennsylvania-based company was advancing for the treatment of solid tumors, in particular melanoma. Th

Pictured: White House/ iStock, Danny Kronstrom There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement with the U.S. The White House has settled on a 15% tariff rate for generic pharmaceuticals coming into the country from the European Union, with President Donald Trump backing off on a previous threat to set import taxes as high as 250% on the pharma industry. The trade agreement with the EU, announced in a statement issued by

India’s pharmaceutical sector is calling on the US government to exclude generic drug imports from a sweeping national security investigation that could trigger major supply disruptions and price spikes. Industry leaders voiced their appeal during a recent meeting with Commerce Minister Piyush Goyal, warning that new US trade actions could threaten affordable medication access in both countries. The US has launched an inquiry under Section 232 of the Trade Expansion Act, 1962, targeting pharmace

iStock, beast01 Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting that FDA Commissioner Marty Makary revisit the decision. Vanda Pharmaceuticals is taking the fight over contested approvals to the top of the FDA’s chain of command, asking Commissioner Marty Makary himself—not merely his office—to revisit the agency’s decision several years ago to clear two generic version of the company’s sleep disorder drug Hetlioz. Desig

iStock, Softulka The drug, for hereditary angioedema, is Ionis’ second wholly owned asset. The FDA on Thursday approved Ionis Pharmaceuticals’ donidalorsen for the prevention of disease attacks in patients with hereditary angioedema. The product will carry the brand name Dawnzera. Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema (HAE), Ionis said in its Thursday news release . The product, which can be used in patients 1

iStock, volodyar Among the problems cited were cat hair, bacterial contamination and instrument defects. The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, raising quality concerns for companies, including Regeneron and Scholar Rock, whose therapies are manufactured there. The problems were reported on Thursday by STAT News , which obtained a copy of the FDA report . They include unaddressed instances of contamination b